Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Overview | 8 | 1 |
| Therapeutics Development | 9 | 4 |
| Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Products under Development by Stage of Development | 9 | 1 |
| Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Products under Development by Therapy Area | 10 | 1 |
| Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Products under Development by Indication | 11 | 2 |
| Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Products under Development by Companies | 15 | 3 |
| Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Products under Development by Universities/Institutes | 18 | 2 |
| Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Therapeutics Assessment | 20 | 7 |
| Assessment by Monotherapy/Combination Products | 20 | 1 |
| Assessment by Mechanism of Action | 21 | 2 |
| Assessment by Route of Administration | 23 | 2 |
| Assessment by Molecule Type | 25 | 2 |
| Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Companies Involved in Therapeutics Development | 27 | 11 |
| Alligator Bioscience AB | 27 | 1 |
| Apexigen, Inc. | 28 | 1 |
| Apogenix GmbH | 29 | 1 |
| Boehringer Ingelheim GmbH | 30 | 1 |
| Bristol-Myers Squibb Company | 31 | 1 |
| Celldex Therapeutics, Inc. | 32 | 1 |
| F. Hoffmann-La Roche Ltd. | 33 | 1 |
| Kyowa Hakko Kirin Co., Ltd. | 34 | 1 |
| Novartis AG | 35 | 1 |
| Seattle Genetics, Inc. | 36 | 1 |
| Zyrnat Biotherapeutics SL | 37 | 1 |
| Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Drug Profiles | 38 | 19 |
| 2C-10 Drug Profile | 38 | 1 |
| ADC-1013 Drug Profile | 39 | 2 |
| APG-1233 Drug Profile | 41 | 1 |
| APX-005M Drug Profile | 42 | 2 |
| BI-655064 Drug Profile | 44 | 2 |
| bleselumab Drug Profile | 46 | 1 |
| BMS-986090 Drug Profile | 47 | 1 |
| CFZ-533 Drug Profile | 48 | 2 |
| FFP-104 Drug Profile | 50 | 1 |
| KGYY-15 Drug Profile | 51 | 1 |
| Monoclonal Antibodies to Agonize CD40 for Lymphoma Drug Profile | 52 | 1 |
| RG-7876 Drug Profile | 53 | 1 |
| SEA-CD40 Drug Profile | 54 | 1 |
| Vaccine to Target CD40 for Membranous Glomerulonephritis Drug Profile | 55 | 1 |
| ZY-11 Drug Profile | 56 | 1 |
| Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Dormant Projects | 57 | 3 |
| Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Discontinued Products | 60 | 1 |
| Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Featured News &Press Releases | 61 | 7 |
| Apr 18, 2016: Seattle Genetics Highlights Data on SEA-CD40 at the American Association for Cancer Research Annual Meeting | 61 | 1 |
| Apr 13, 2016: Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences | 61 | 1 |
| Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn s Disease with anti-CD40 Monoclonal Antibody | 62 | 1 |
| Nov 17, 2015: Apexigen Presents Positive Data for APX005M in Podium Presentation at Immune Checkpoint Inhibitors (ICI) Europe | 62 | 1 |
| Nov 06, 2015: Apexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate APX005M at SITC 2015 Meeting | 63 | 1 |
| Jun 16, 2015: Apexigen Doses First Patient in Phase 1 Clinical Trial of Its Immuno-oncology Therapeutic Antibody APX005M | 64 | 1 |
| May 28, 2015: Alligator Bioscience Phase 1 Trial Benefits from Cobra Biologics maxXpress Platform | 64 | 1 |
| Apr 27, 2015: First Patient Dosed by Alligator Bioscience in a Clinical Phase 1 Multicenter Trial | 65 | 1 |
| Apr 07, 2015: Alligator Bioscience Starts a Clinical Phase 1 Multicenter Trial | 65 | 1 |
| Feb 17, 2015: Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced Solid Tumors | 66 | 1 |
| Dec 05, 2012: Boehringer Ingelheim And Apexigen Sign Manufacturing Agreement For Process Development And Early Stage Clinical Supply | 66 | 2 |
| Appendix | 68 | 2 |
| Methodology | 68 | 1 |
| Coverage | 68 | 1 |
| Secondary Research | 68 | 1 |
| Primary Research | 68 | 1 |
| Expert Panel Validation | 68 | 1 |
| Contact Us | 68 | 1 |
| Disclaimer | 69 | 1 |